The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis | Zendy

Hasan Mutlu | Zendy; Hakan Bozcuk | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

The optimal upfront therapy in metastatic hormone-sensitive prostate cancer: A network meta-analysis

Author(s) -

Hasan Mutlu,

Hakan Bozcuk

Publication year - 2021

Publication title -

journal of cancer research and therapeutics

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.475

H-Index - 39

eISSN - 0973-1482

pISSN - 1998-4138

DOI - 10.4103/jcrt.jcrt_23_20

Subject(s) - enzalutamide , docetaxel , abiraterone acetate , medicine , oncology , prostate cancer , population , androgen deprivation therapy , hazard ratio , cancer , confidence interval , androgen receptor , environmental health

Prostate cancer (PC) is one of the most common cancer types in men. In addition to androgen-deprivation therapy (ADT), new generation agents have provided survival advantages to patients with metastatic hormone-sensitive PC (mHSPC). In this analysis, we aimed to determine the most effective approach for treating and suppressing mHSPC using network meta-analysis (NMA).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research